Based on the Harmony Biosciences Holdings stock forecast from 7 analysts, the average analyst target price for Harmony Biosciences Holdings is USD 47.62 over the next 12 months. Harmony Biosciences Holdings’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Harmony Biosciences Holdings is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Harmony Biosciences Holdings’s stock price was USD 33.05. Harmony Biosciences Holdings’s stock price has changed by -7.55% over the past week, -4.48% over the past month and +27.51% over the last year.
No recent analyst target price found for Harmony Biosciences Holdings
No recent average analyst rating found for Harmony Biosciences Holdings
Company Overview Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. Read Less
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism...Read More
Frequently Asked Questions About Harmony Biosciences Holdings (HRMY) Stock
Based on ratings from 7 analysts Harmony Biosciences Holdings's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 11 buy, 2 sell and hold ratings.
Unfortunately we do not have enough data on HRMY's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for HRMY is USD 47.62 over the next 12 months. The maximum analyst target price is USD 59 while the minimum anlayst target price is USD 28.
HRMY stock's Price/Earning ratio is 15.68.
Our analysis grades HRMY stock's Price / Earning ratio at F. This means that HRMY stock's Price/Earning ratio is above 65.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this HRMY may be a overvalued for its sector.
The last closing price of HRMY's stock was USD 33.05.
The most recent market capitalization for HRMY is USD 1.89B.
Based on targets from 7 analysts, the average taret price for HRMY is projected at USD 47.62 over the next 12 months.
This means that HRMY's stock price may go up by +44.07% over the next 12 months.
We can't find any ETFs which contains Harmony Biosciences Holdings's stock.
As per our most recent records Harmony Biosciences Holdings has 246 Employees.
Harmony Biosciences Holdings's registered address is 630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462.
You can get more information about it from Harmony Biosciences Holdings's website at https://www.harmonybiosciences.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Harmony Biosciences Holdings (HRMY) Stock
Based on ratings from 7 analysts Harmony Biosciences Holdings's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 11 buy, 2 sell and hold ratings.
Unfortunately we do not have enough data on HRMY's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for HRMY is USD 47.62 over the next 12 months. The maximum analyst target price is USD 59 while the minimum anlayst target price is USD 28.
HRMY stock's Price/Earning ratio is 15.68.
Our analysis grades HRMY stock's Price / Earning ratio at F. This means that HRMY stock's Price/Earning ratio is above 65.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this HRMY may be a overvalued for its sector.
The last closing price of HRMY's stock was USD 33.05.
The most recent market capitalization for HRMY is USD 1.89B.
Based on targets from 7 analysts, the average taret price for HRMY is projected at USD 47.62 over the next 12 months.
This means that HRMY's stock price may go up by +44.07% over the next 12 months.
We can't find any ETFs which contains Harmony Biosciences Holdings's stock.
As per our most recent records Harmony Biosciences Holdings has 246 Employees.
Harmony Biosciences Holdings's registered address is 630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462.
You can get more information about it from Harmony Biosciences Holdings's website at https://www.harmonybiosciences.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HRMY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
